Tags Posts tagged with "oxis"

oxis

    0 544

    TAMPA, Fla., Sept. 9, 2015 /PRNewswire/ — Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the company will be presenting at the 2015 Rodman & Renshaw Global Investment Conference in New York City.

    Oxis Biotech Chairman and CEO Anthony J Cataldo is scheduled to present to investors on Thursday September 10, 2015 at 3:45pm. Mr. Cataldo will present details of Oxis’ latest licensing agreement for DT2219ARL. DT2219ARL targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.  When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug’s cytotoxic payload.  DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

    “We are very excited to update the investment community on the exciting developments at Oxis. DT2219ARL has the potential to be important and significant cancer drug,” said Anthony J. Cataldo, Chairman and CEO of Oxis Biotech.

    At the conference there will be opportunities for investors to meet one on one with Mr. Cataldo. Mr. Cataldo will be meeting with institutional investors and analysts throughout the week in New York. Investors interested in meeting with Mr. Cataldo should contact investor relations at the number provided below.

    About Oxis Biotech, Inc.

    Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs.  OXIS’ lead drug candidate, DT2219ARL is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload.  DT2219ARL simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.  When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug’s cytotoxic payload.  DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.  OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions.  In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.  OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC).  In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.  For more information about Oxis Biotech, please visit http://www.oxis.com.

    Forward-Looking Statements

    Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially.  Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results.  Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact

    Oxis International Inc.
    Investor Relations
    800-304-9888

    0 1486

    Oxis Biotech Licenses Exclusive Worldwide Rights To Novel Cancer Therapy

    TAMPA, Fla., Sept. 8, 2015 /PRNewswire/ — Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. (OXIS) and (Euronext Paris: OXI.PA) announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

    DT2219ARL is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development, and is also expressed on most B-cell mature lymphoma cells and leukemia cells.1 CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia, and often is co-expressed with CD19 on mature B-cell malignancies such as lymphoma.2

    DT2219ARL targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug’s cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

    Twenty-five patients with advanced B-cell lymphoid malignancies expressing CD19 and/or CD22 were enrolled in a clinical study to evaluate DT2219ARL in a phase 1 FDA study. Patients were enrolled that had previous failed chemotherapy, immunotherapy, and/or hematopoietic (bone marrow or stem cell) transplantation. Patients received a single course of DT2219ARL according to study rules. Adverse events were successfully managed and included weight gain, low albumin, transaminitis, and fever were transient grade 1–2 and occurred in patients at the higher doses tested (>/=40µg/kg/day). Durable objective responses occurred in 2 patients at these higher doses. A complete response occurred in the only patient given a second cycle of therapy that had a 70% cancer reduction after the first cycle of therapy… The patient has been in remission for a year now. Correlative studies showed a surprisingly low incidence of neutralizing antibody (30%) production that could be related to the drug’s ability to suppress antibody responses. For further information about the clinical trial, see Bachanova, V., et. al., Clin Cancer Res; 21(6) March 15, 2015.

    “We are pleased to have the opportunity to further develop DT2219ARL”, said Anthony J. Cataldo, Chairman and CEO of Oxis Biotech. There were several other major companies interested in acquiring this technology and we are honored to be the partner selected for this. This cancer therapy along with our existing platform, puts us in the forefront of next generation therapy along side companies like Amgen Biologics (AMGN), Seattle Genetics, Inc. (SGEN). When I started Lion Biotechnologies, Inc. (LBIO) in February of 2011, I knew that cell therapy was the next wave of cancer therapies to come. Kite Pharma (KITE) and Juno Therapeutics (JUNO) followed and demonstrated this. Now the future is targeted immunotherapy and with DT2219ARL, we are poised to lead this effort. “We believe DT2219ARL holds great promise as a treatment for a number of B-cell malignancies”, Mr. Cataldo further added.

    “We are very excited to continue this work with Oxis Biotech, said Dr. Daniel A Vallera, professor, University of Minnesota Masonic Cancer Center. “A stellar commercialization partner is critical at this juncture since our FDA trial is scheduled to resume with a superior dose scheduling involving multiple cycles of therapy. We expect even better responses with more aggressive treatment and need to move forward quickly.”
    B-cell malignancies represent a diverse number of cancers of the blood cells, lymph nodes and other parts of the lymphatic system, including non-Hodgkin’s lymphomas, certain types of leukemia, and myelomas. Examples include chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma.3

    According to the Leukemia and Lymphoma Society, an estimated 1,185,053 people in the U.S. are either living with or are in remission from leukemia, lymphoma or myeloma, and approximately every 10 minutes someone in the U.S. dies from a blood-related cancer.4

    About Oxis Biotech, Inc.

    Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS’ lead drug candidate, DT2219ARL is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. DT2219ARL simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug’s cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech, please visit http://www.oxis.com.

    Forward-Looking Statements

    Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact
    Oxis International Inc.
    Investor Relations
    800-304-9888

    1 Scheuermann RH, Racila E., Leuk. Lymphoma (1995) 18:385–97.

    2 Cesano A, Gayko U., Semin. Oncol. (2003) 30:253–7.

    3 National Comprehensive Cancer Network (2014).

    4 Leukemia and Lymphoma Society FACTS 2014-2015.

      0 2777

      Oxis Biotech, a wholly-owned subsidiary of Oxis International, Inc. (OTCQB: OXIS) is a biotech company that we introduced to you back in January 2015 that gained approximately 250% just 3 months after we initiated coverage on the company. This emerging biotech, led by an experienced CEO who once before took an OTC listed biotech with a market cap of about $2M to a NASDAQ main listed company now sporting a $325M market cap, has just released potentially game-changing news.

      OXIS has just taken a TREMENDOUS step forward by executing an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemia and lymphomas. But this isn’t just any ordinary infant drug. DT2219ARL has already completed an FDA Phase I study with promising results!

      The Story Behind the Drug

      The University of Minnesota posted an article on their website detailing the extraordinary work done behind the development and success of DT2219ARL. You can read the entire article here: https://give.umn.edu/stories/clinical-trial-triumph

      The article details how In June of 2012, University of Minnesota physics professor Cynthia Cattell, Ph.D., discovered she had aggressive B-cell lymphoma, a blood cancer that required immediate, intensive treatment. That treatment—chemotherapy, radiation, and two bone marrow transplants—was brutal, leading Cattell into and out of the hospital for months. Worse, it wasn’t working; her cancer kept growing back. Then, her doctor told her about a Phase I clinical trial underway at the U and asked if she was interested. That clinical trial was that of DT2219ARL.

      Fast forward some time and one month after her second round of DT2219ARL, Cattell’s tumors have vanished. And almost a year later, she remains in complete remission.

      Dr. Daniel A Vallera, professor at the University of Minnesota Masonic Cancer Center responsible for developing DT2219ARL, got a rare opportunity to come face to face with Cattell, who had gone into complete remission because of a drug he had developed.

      Cattell explained, “To meet the person who developed the drug that saved your life? Incredible. I’m so grateful for the work he’s done, and I hope that by participating in the trial, I’ve helped them learn more about the drug and that it will help save other people.”

      What This Means for OXIS

      We believe this is an absolute game changer for OXIS. This could be the drug that takes OXIS to the next level as a public company. In an interview conducted by the Wolf of Weed Street earlier this year, OXIS CEO Tony Cataldo made it very clear that he believed OXIS would up-list to a major exchange at some point this year. He stated how he was implementing the same strategy and process with OXIS as he did with Lion Biotechnology (LBIO), formerly Genesis Biopharma, the biotech company that went on to up-list to the NASDAQ and reach a recent 52-week high of $15.03. And with this news announcement, we believe OXIS now has enough assets in their pipeline to conduct a large institutional raise with a major investment bank and complete an up-list to a major exchange.

      Having a drug with positive Phase I clinical trial results should make OXIS a primary target for several investment funds looking to cash in big on the next major breakthrough in cancer therapy. The biotech industry overall has been the hottest sector in the market this year. Couple that with Cataldo’s past success in biotech and we expect OXIS to have their pick of the litter when it comes time for a major institutional raise to proceed with advanced stage FDA trials and eventually commercializing DT2219ARL.

      Cataldo also mentioned how he would only do an up-list with a simultaneous institutional raise because a reverse split would be necessary to qualify for a NASDAQ listing since the current share price is around $0.025 with a market cap of $12.9M. Needless to say we expect the addition of DT2219ARL to drastically increase the market value of OXIS. The current share price also happens to be about the same share price Genesis Biopharma was before conducting a reverse split, becoming Lion Biopharma, and up-listing to the NASDAQ, which was all done with a simultaneous institutional raise. Hmmmm, sound familiar???

      Listen to the interview from January 2015 here: http://marijuanastocks.com/wolfofweedst-interviews-oxis-ceo-tony-cataldo/

      As a company, OXIS has been relatively quiet lately issuing just a couple press releases with no real major announcements and now we know why. Cataldo has been hard at work to land the exclusive worldwide rights to DT2219ARL. In the press release, Cataldo stated how several other major biotech companies were interested in acquiring DT2219ARL. He went on to say, “This cancer therapy along with our existing platform, puts us in the forefront of next generation therapy alongside companies like Amgen Biologics (AMGN) and Seattle Genetics, Inc. (SGEN).” AMGN and SGEN trade at $147 and $40 a share with market caps of $111.4B and $5B respectively.

      Dr. Daniel A Vallera said, “We are very excited to continue this work with Oxis Biotech.” He continued, “A stellar commercialization partner is critical at this juncture since our FDA trial is scheduled to resume with a superior dose scheduling involving multiple cycles of therapy. We expect even better responses with more aggressive treatment and need to move forward quickly.”

      The FDA Phase I Study

      Twenty-five patients with advanced B-cell lymphoid malignancies expressing CD19 and/or CD22 were enrolled in a clinical study to evaluate DT2219ARL in a phase 1 FDA study. Patients were enrolled that had previous failed chemotherapy, immunotherapy, and/or hematopoietic (bone marrow or stem cell) transplantation. Patients received a single course of DT2219ARL according to study rules. Adverse events were successfully managed and included weight gain, low albumin, transaminitis, and fever were transient grade 1–2 and occurred in patients at the higher doses tested (³40µg/kg/day). Durable objective responses occurred in 2 patients at these higher doses. A complete response occurred in the only patient given a second cycle of therapy that had a 70% cancer reduction after the first cycle of therapy… The patient has been in remission for a year now. Correlative studies showed a surprisingly low incidence of neutralizing antibody (30%) production that could be related to the drug’s ability to suppress antibody responses. For further information about the clinical trial, see Bachanova, V., et. al., Clin Cancer Res; 21(6) March 15, 2015.

      0 1904

      Oxis Biotech Executes Amended Option Agreement With the University of Pittsburgh

      TAMPA, FL–(Marketwired – August 04, 2015) – Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. (OXIS) and (EURONEXT PARIS: OXI.PA) announced today the execution of the amendment to its current exclusive option agreement with the University of Pittsburgh related to certain patent rights developed by Dr. Xiang-Qun Xie, Associate Dean for Research Innovation and Professor, Pharmaceutical Sciences, School of Pharmacy. The patent rights relate to the addition of certain novel compositions-of-matter which could prove useful as therapeutics for the treatment of various human diseases.

      “We are pleased to have the opportunity to expand our current relationship with the University of Pittsburgh,” said Anthony J. Cataldo, Chairman and CEO of Oxis Biotech.

      The novel p62 inhibitors developed by Dr. Xie and his colleagues at the University of Pittsburgh demonstrate inhibition of multiple myeloma cell growth without toxicity to normal bone marrow stromal cells. Bone marrow stromal cells are involved in hematopoiesis and certain inflammatory processes.

      Multiple myeloma is a type of cancer that forms in white blood cells, and affects about 26,850 people annually in the USA causing about 11,240 deaths per year. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Multiple myeloma is also characterized by destructive osteolytic bone lesions (rounded, punched-out areas of bone), diffuse osteoporosis, bone pain, and the production of abnormal proteins which accumulate in the urine. Plasma cell leukemia, a condition in which plasma cells comprise greater than 20% of peripheral leukocytes, is typically a terminal stage of multiple myeloma and is associated with short survival.

      Multiple myeloma is marked by abnormal protein production, and frequently is characterized by bone disease – a major cause of patient morbidity. Multiple myeloma induced bone disease is marked by holes in the bone and intense pain due to increased osteoclast bone degradation activity and highly suppressed or absent osteoblast bone remodeling (growth) activity. Cell adhesive interactions between multiple myeloma cells and bone marrow stromal cells activate multiple signaling pathways that enhance cancerous tumor growth and bone destruction while suppressing new bone formation and contributing to drug resistance.

      The recent improvements in overall survival and remission duration in multiple myeloma are largely due to the advent of novel therapeutic agents. These therapeutic agents exploit a tumor cell’s dependency on clearance mechanisms for abnormal or mutant cellular proteins. Tumor cells are very sensitive to any type of inhibition of this clearance mechanism which when inhibited leads to an antiproliferative and pro-apoptotic effect on the tumor cells mediated by induction of endoplasmic reticulum stress, activation of caspases, and generation of reactive oxygen species.

      p62 is a protein having multiple biological roles involving cell signaling, cell receptor internalization, and protein degradation/turnover. p62 has been reported to be a regulator of inflammation, neurogenesis, increased osteoclastogenesis (bone destruction), adipogenesis and T-cell differentiation. One of the more interesting functions of p62 is the regulation of NF-kappa-B, which is the master regulator of innate immunity and aging. p62 is also found in inclusion bodies containing polyubiquitinated protein aggregates which are present in several neurodegenerative diseases such as Parkinson, Alzheimer, and Huntington’s diseases. Additionally, p62 acts as s shuttling factor for the delivery of damaged biomolecules to the proteasome for destruction and removal.

      By selectively inhibiting p62 in multiple myeloma cancer cells, stress is induced in the multiple myeloma cancer cells due to the accumulation within the cells of damaged biomolecules that cannot be destroyed via the normal function of the proteasome. As a result of the stress placed on the cancer cells by inhibition of p62, the cancer cells undergo a biological process known as autophagy which results in their destruction.

      OXS-4235 is a first-in-class therapeutic candidate targeting the inhibition of p62 for the treatment of multiple myeloma and osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma tumors, decrease osteolytic lesions, and the ability to help restore normal bone remodeling resulting in healthy bone. In addition to direct killing of multiple myeloma cells, OXS-4235 was found to also inhibit TNF-alpha mediated osteoclast formation. TNF-alpha is a major suppressor of osteoblast differentiation. TNF-alpha is upregulated in the bone marrow microenvironment resulting from multiple myeloma cell – stromal cell interactions. Reducing osteoblast suppression in the multiple myeloma bone marrow microenvironment via the inhibition of TNF-alpha, normal bone remodeling is restored. “OXS-4235’s dual mechanism of action, and no observed toxicity in mouse models of multiple myeloma is very exciting”, stated Anthony Cataldo, Chairman and Chief Executive Officer of Oxis Biotech, Inc.

      About Oxis Biotech, Inc.

      Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS’ lead drug candidate OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech, please visit http://www.oxis.com.

      About the University of Pittsburgh School of Pharmacy

      Chartered in 1878, the School of Pharmacy is the oldest of the University of Pittsburgh’s Schools of the Health Sciences, and is ranked in the top 10 nationwide. The School of Pharmacy is on the forefront of educating future practitioners with its four-year Pharm. D. program, and is a leader in research with endeavors ranging from patient care outcomes and human clinical research to research in molecular genetics. Like the other Schools of the Health Sciences, the School of Pharmacy is also affiliated with the internationally renowned University of Pittsburgh Medical Center (UPMC) which provides the region’s largest network of tertiary, specialty, and community hospitals. Collectively, these facilities provide one of the nation’s most complete health centers for teaching, patient care, and research in the health sciences. For more information about the School of Pharmacy, please visit http://www.pharmacy.pitt.edu.

      Forward-Looking Statements

      Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
      Contact:
      Contact

      Oxis Biotech, Inc.
      Investor Relations
      800-304-9888

        1 4978

        Being that OXIS is one of the most followed cannabis companies by our readers, it is no surprise that we have received a lot of questions about the filing OXIS released on May 8th, 2015, regarding an upcoming reverse split. Like we stated in an earlier article published by Marijuana Stocks, too many people have a negative stigma when it comes to reverse splits. And for the most part they aren’t wrong, but I stress “for the most part.”

        Not every reverse split is a bad thing. In fact, there have been several times in just the past couple years where reverse splits worked greatly to benefit a company and its shareholders. And it’s no coincidence that one of those times involved current OXIS CEO Tony Cataldo.

        The Facts

        In the filing, OXIS states, “ to effect a reverse stock split of the Company’s common stock at a ratio to be determined by the Board prior to the effective time of the amendment (the “Effective Time”) of not less than one-for-fifty and not more than one-for-two hundred fifty.” The exact ratio and timing of the split is yet to be determined.

        The last time Mr. Cataldo was heading a biotech company that conducted a reverse split he was CEO of Genesis Biopharma (an OTC listed company at the time) which later merged with and changed its name to Lion Biotechnologies and traded under symbol LBIO. On September 25, 2013, the company announced a 1-for-100 reverse stock split. The week following the announcement the new post-split price of LBIO stock was about $5.75. Well, earlier this year LBIO hit a 52-week high of $15.03. That’s a 161% gain since the reverse split. LBIO is also now a main listed NASDAQ company.

        Mr. Cataldo has been quoted in several interviews about his goal of up-listing OXIS to the NASDAQ this year and mentioned a reverse split would be necessary to achieve this goal by satisfying the national exchange’s minimum bid and/or closing price requirement. So, this announcement shouldn’t come as a surprise to people. This CEO is doing exactly what he said he was going to do and what he feels is necessary to bring OXIS to a main listed NASDAQ biotech company.

        The filings goes on to explain the reasoning behind the split, “The Board believes that a reverse split may be desirable because it could assist the Company in meeting the requirements for initial listing on NASDAQ by helping to raise the bid or closing price for our common stock…If our common stock is listed on NASDAQ, the liquidity of our common stock and coverage of our company by security analysts and media could be increased, which could result in higher prices for our common stock than might otherwise prevail…Additionally, certain investors will only purchase securities that are listed on a national securities exchange, and such listing could thus increase our ability to raise funds through the issuance of our common stock or other securities convertible into our common stock…”

        Our Take

        In the near future, OXIS is going to conduct a reverse split anywhere from 1-for-50 up to a possible maximum of 1-for-250. Although most reverse splits on the OTC are done for the wrong reasons and lead to shareholder dilution, a reverse split done with a main purpose of up-listing to a major exchange is a very good sign. No matter which way you look at it, the benefits of being listed on the NASDAQ rather than the OTC are priceless. A company listed on the NASDAQ has easier access to institutional money with a much smoother capital raise process and has the ability to have their common stock acquired by hedge funds, mutual funds, ETFs, pension funds, and broker dealers around the world. Most large firms are not able to purchase OTC listed securities. This new exposure should greatly increase OXIS’ liquidity and market efficiency creating a much better environment for shareholders.

        It appears to us that Mr. Cataldo is following through with his plan of up-listing to the NASDAQ and so far has done everything that he said he was going to do. He has been down this road before with LBIO and had tremendous success in doing so.

        What We Are Looking For

        In an interview earlier this year, Mr. Cataldo said he would not conduct a reverse split unless it was coupled with a large institutional money raise and/or an up-listing to a major exchange. We are going to be watching closely for a follow up announcement regarding one of those two things. This would confirm that the reverse split is indeed for the sole purpose of meeting the minimum bid requirement for the NASDAQ.

        What This All Means For Shareholders

        Absolutely nothing. Confused? Don’t be. Because your equity position will NOT change in value at all. The company’s market cap remains exactly the same as does the value of your equity position.

        For example, if OXIS conducts a 1-for-100 reverse split, the new price of OXIS common stock will be $3.30 based on a current price of $0.033. In addition, if you currently own 100,000 shares at $0.033 a share for a value of $3,300 you will now own 1,000 shares at $3.30 a share for the very same value of $3,300

        If OXIS does up-list to the NASDAQ, shareholders will most likely enjoy a much more liquid, fair and efficient marketplace with the ability to access capital from some of the world’s largest investment banks and investment firms. Being a main listed company would also most likely result in increased media exposure and something OXIS would never get being an OTC company, buy and sell side analyst coverage.

        Interest in cannabis companies has continued to grow in 2015 as more states have begun to implement legalization efforts; these including options for both medical and recreational use.

        After more states like Texas have put wheels in motion for legalization efforts, more attention has begun to build and the 2015 market for cannabis stocks has started to look much different than the uncertainty that was seen last year.  Companies like Oxis International (OXIS), Pazoo, Inc. (PZOO), and Totally Hemp Crazy Inc (THCZ) have all seen record 6-month highs this year as a flood of positive news and a more informed investment community have bolstered movement within the market.

        Oxis International,  (OXIS) saw highs of $0.07 less than 45 days ago.  Earlier this week, Oxis announced its wholly owned subsidiary, Oxis Biotech, had brought on Cassian Yee, M.D.  Yee is a Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center as well as Professor, Department of Immunology, Division of Cancer Medicine, and Director, Solid Tumor Cell Therapy, Center for Cancer Immunology Research at the University of Texas MD Anderson Cancer Center.

        “We are very excited to have the opportunity to work with Cassian again, and we look forward to his helping us build Oxis into a leading cancer immunotherapy company,” said Anthony J. Cataldo, Chairman and Chief Executive Officer of Oxis Biotech.

        Thursday afternoon Oxis shares battled back from intra-day lows of $0.03 to close the Thursday session at $0.0322, up 7% from those lows. Since the opening day of 2015, Oxis has moved up by as much as 100% (Jan 2 $0.035 open to March 31 High of $0.07)

        Pazoo Inc. (PZOO) has also seen a jump in price since the beginning of the year.  After opening on January 2 at $0.0194, PZOO saw it’s record high on April 27 ($0.0204).  Though the stock had fallen briefly, in February, the recent rally in the market may have been spawned by new company developments.  This month Pazoo announced that members of its staff will be attending several investment and marijuana conferences over the month of May. Pazoo is also announced it will have a booth at the 4th Annual Marijuana Business Conference and Expo, America’s largest national cannabis trade show, being held in Chicago, May 19-21.

        During the past week Pazoo has maintained a price channel between $0.01-$0.0124.

        Totally Hemp Crazy Inc. (THCZ) may have seen one of the largest moves in price of many cannabis stocks.  After opening the year at $0.012, Totally Hemp Crazy saw highs of $0.32 at the beginning of April and tested these highs once more just before the beginning of May. Totally Hemp has gained notoriety for its novel hemp infused beverages under the Rocky Mountain High brand. This week it was announced that the company’s CEO Jerry Grisaffi will be interviewed on WWNN – 1470AM, a Beasley Broadcasting Network station. The broadcast can be heard live on south Florida radio WWNN -1470AM and streamed live on video TV at www.wwnnradio.com. Mr Grisaffi will be interviewed, Friday, May 15, 2015 at noon EDT. Grisaffi recently stated, “The Rocky Mountain High retail product launch is underway and based on initial sales and consumer reactions, we are convinced we have something special. In just a few short months, production has exceeded 1,000,000 units and we have another larger production run scheduled for June. We are confident our rapid growth will lead to a nationwide hemp infused drink sensation. Based on the current feedback from other parties, we are not alone in that belief.”

        About marijuanastocks.com

        MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

        Legal Disclaimer

        Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

        MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC,  which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

         

        Contact Information:

        marijuanastocks.com
        800-539-4313
        pr@marijuanastocks.com


        SOURCE:
        MarijuanaStocks.com

          0 2229

          Over the past year or so, Marijuana Stocks has evolved into becoming the go-to online destination for anything marijuana finance related. Our content and market analysis is second to none as we have been able to not only educate and inform our readers but also help them consistently profit from this budding industry. As a result, we are actively being sought out for our input and expertise regarding the marijuana industry. In this video, Red Chip, a world leading small-cap research and IR firm, interviewed Michael Perinotti, co-founder of MarijuanaStocks.com, to get his take on what the future of the marijuana industry may look like.

          In the video, Mr. Perinotti discusses the current state of the market while giving a longer term outlook on where the opportunity exists today for investors. He states how the Marijuana Stocks team currently has a strong focus on cannabis biotech companies making a push to develop drugs using cannabinoid molecules to treat certain ailments and diseases. He mentions three companies by name specifically, GW Pharma (GWPH), Insys Therapeutics (INSY), and Oxis International (OXIS).

            0 1940
            OXIS has been a topic of conversation as well as a very profitable trade opportunity on / for MarijuanaStocks.com & WolfofWeedStreet.com. The Wolf sent out his “Morning Howl” this morning (5/5) providing a GREAT update on OXIS please read below.

            “OXIS: I’m starting to think that the time to trade and accumulate this one at the current level is coming to a close. Volume the last week or so has been consistent with a big spike two Fridays ago end of day, touching .0395. The channel Oxis has been in is exceptionally tight and I feel like the .04 level will be retested sooner rather than later. As for my position it’s still intact at 750k, and the reason I’ve been In this as long as I have is that I like Biotech, but mostly because I feel like there are trials and drug results out there that we don’t know about. My hunch is that management isn’t standing idly by. I’m using PMCB as a reference not just because it’s biotech but because the share structures are somewhat similar float wise. PMCB’s float is 529m vs Oxis 500m. There’s also an O/S difference of about 107m with Pmcb at 707m and Oxis at 600m even. When it comes to the A/S Oxis wins with an A/S of 600m vs PMCB 1.49 billion which is good considering Oxis can’t dilute. So why the share difference? Well PMCB does a lot of promotion where Oxis CEO Tony Cataldo builds a biotech company like LBIO. Not sure there are many people in the MMJ space that can show a formula that actually works. Food for thought u guess, but I like Oxis going into the summer and I think the spring is loaded for a run, 25-50% wouldn’t shock me.”

            2 3770

            CORAL GABLES, FL / ACCESSWIRE / April 16, 2015 / Cannabis stocks are in turnaround. After new states recently legalized cannabis for recreational use and many other states for medicinal use. The bottom line is Cannabis is showing progress, and this could lead to more money to make as an investor. After seeing the numbers from last year both from a revenue standpoint and a tax generation focus, many more individuals, businesses, and investors are becoming more educated on the subject. There have even been new state and federal initiatives put in motion to further open the market throughout the US.

            The public sector is no stranger to this growth. Companies have pushed for new growth initiatives by several different means including products, services, and even biotechnology. With companies like Oxis International (OXIS), Cannabiz Mobile (LGBI), and Totally Hemp Crazy (THCZ), the myriad of options continues to grow for investors in today’s market.

            Oxis International, Inc. (OXIS) is a biotechnology company focused on cannabinoid therapy development and commercialization. On April 14th 2015, OXIS International Inc. (OXIS) announced that its CEO will present in Business of Biotech 2015 at the Moffitt Cancer Center. OXIS continues to make strides with its P62-ZZ Chemical Inhibitor and Therapeutic Potential for Multiple Myeloma patent application. Over the last week, shares of OXIS have traded in a range from $0.028-$0.0378.

            Cannabiz Mobile (LGBI) markets a mobile media platform that utilizes digital media and traditional media such as print, radio and television to help businesses build customer databases via text/sms opt-ins through keyword/shortcode combinations. The company also has a subscription based mobile and digital media solution that enables care-givers, dispensaries, hydroponic and ancillary product retailers the ability to create, deploy and analytically measure mobile marketing campaigns.

            Just recently Cannabiz announced that it has secured the Trademark name Canna Bizcard and has executed a license and re-branding agreement with Code2action Inc. for its proprietary mobile business card platform C2A MobiCard. The Company will begin marketing the Canna Bizcard, a mobile business card solution that combines the power of social media sharing with text/sms and email marketing for businesses in various states that have legalized medical and/or recreation MJ. Over the last 10 days, LGBI has seen highs of $0.0025 and lows of $0.0011.

            Totally Hemp Crazy Inc. (THCZ) has seen significant increases in price with much attention being placed on its hemp infused beverage, Rocky Mountain High Brand. The company also just signed a bottle distribution agreement with a Dr. Pepper Bottling Company Distributor and over the course of the last month THCZ has seen a jump of as much as 650% from its lows of $0.04 to its 52-week high of $0.32. On Wednesday, THCZ closed at $0.1899.

            About marijuanastocks.com

            MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

            Legal Disclaimer

            Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

            MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

            Contact Information:

            marijuanastocks.com
            800-539-4313
            pr@marijuanastocks.com

            SOURCE: MarijuanaStocks.com

              1 3159

              On March 31st, we had the privilege of moderating an investor conference call with OXIS CEO Tony Cataldo.  Below are what we believe are the 5 key points to take away from the call along with a recording of the entire call for your listening pleasure.

              FULL CONFERENCE CALL RECORDING

              1. Possible up listing to the NASDAQ this year.

              This seemed to be the overwhelming theme of the call as Mr. Cataldo mentioned several times his goal of up listing to the NASDAQ this year. He recognized certain things that needed to be done first, obviously, but said he is confident that this could happen this year. He was very clear in stating that he is aggressively moving forward toward achieving this goal.

              1. Institutional Interest & Support

              As we expected, Mr. Cataldo confirmed that he is receiving high institutional interest. With the overwhelming success of his previous biotech company, we foresaw this happening with OXIS. He openly said there have been both high net worth individuals and institutions that already offered him money. This goes hand-in-hand with the possible NASDAQ up listing as there are no limitations on institutional involvement of a main listed company. He specifically said he has been in talks with two groups and is working on a registered direct and institutional raise to couple with a NASDAQ up listing. A large institutional raise would be a game changer for OXIS in addition to possibly sparking analyst coverage.

              1. T-Cell Therapies

              Mr. Cataldo has a lot of experience with T-Cell therapies and was quoted saying he loves them. T-Cells were the basis for his success with LBIO and he is now bringing them to OXIS. But what is T-Cell therapy and what does it mean for OXIS?

              Well, OXIS is now also developing bispecific immune cell engagers, a class of monoclonal antibodies that direct a person’s immune system to attack cancer cells.  More specifically, bispecific immune cell engagers consist of the part of the monoclonal antibody which recognizes an immune cell such as a cytotoxic T-cell, and the part of a different monoclonal antibody which recognizes the cancer cell.  When administered as a therapeutic, the bispecific immune cell engager brings cytotoxic T-cells in contact with the target cancer cell where the cytotoxic T-cell kills the cancer cell.

              This technique could work wonders for OXIS’ Myeloma and Triple Negative Breast Cancer drug treatments. But it’s Cataldo and his team’s experience and past success with T-Cells at Lion that has us most excited about this development.

              1. Something is Coming

              There were several times throughout the call that Mr. Cataldo said things along the lines of, “I cannot talk too much about that at this time,” and, “We will be updating investors through an 8K and press release,” which to us sounds like a very confident CEO that has something up his sleeve. When asked to elaborate on certain topics like updated drug data and T-Cell therapies, Mr. Cataldo casually said to watch for an 8K and press release. However, he made one comment that really resonated with us. When touching on their T-Cell therapies, he made mention of new data that he feels will be valued similar to KITE ($2.5B Market Cap) and JUNO ($5.5B Market Cap). These are two NASDAQ listed biotech companies with incredible market caps.

              We all really wished to get more information out of him but legally he was not able to discuss certain things that have not yet been made public or perhaps aren’t finalized. We don’t know if it will be one announcement or several, but we certainly will have our eyes peeled to the newswire.

              1. A Winning Formula

              Mr. Cataldo has had tremendous success in the public biotech space. He founded a company called Genesis Biopharma and later merged it with Lion Biopharma to trade under ticker symbol LBIO. Genesis was once an OTC company with a measly $2Million market cap but now, under the new name of Lion Biopharma, trades on the NASDAQ and sports an impressive $540Million market cap. Although Cataldo has since moved on from LBIO, all of the original data and structure he developed and implemented nearly 5 years ago are still in place. He said, “If it isn’t broke, don’t try to fix it,” when asked if he is implementing the same strategy in OXIS as he did in LBIO. He said he is literally replicating the model.

              With LBIO, Mr. Cataldo was able to successfully acquire high-quality drug data and licensing rights from the world’s top scientists even when big pharma giants like Pfizer and Johnson & Johnson wanted them. And he was able to do this by putting together a beyond rock solid all-star management team and scientific advisory board that brought value to the table and were able to execute, plain and simple.

              Well, now Cataldo is doing the exact same thing with OXIS as he has brought on several of the same scientists and key personnel that developed Genesis and Lion. Their strategy has proven to be successful and the team has proven that they are more than capable of taking a small OTC biotech company and turning it into a fully listed NASDAQ.

               

              Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

              We are your #1 source for all things Marijuana Stocks, Subscribe Below!

              Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
              Ad Placements